Loading stock data…
DMRA
$24.36+0.20 (+0.83%)
Market ClosedLast close May 11
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Damora Therapeutics, Inc. in the Healthcare sector is trading at $24.36. The stock is currently 36% below its 52-week high of $38.33, remaining 37.2% above its 200-day moving average. Technical signals show neutral RSI of 37 and bearish MACD signal, explaining why DMRA maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 37) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.36
Potential Upside
5%
Whystock Fair Value$25.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that target...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.54B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-87.29%
Volume
Today's trading volume
250,720
Recent News
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders
Damora Therapeutics recently overhauled its leadership team, appointing Jennifer Jarrett as President and CEO and naming Brian Burkavage as principal financial and accounting officer following the planned departure of CFO Lori Firmani effective May 1, 2026. The combination of Jarrett’s oncology and investment banking background with a new finance lead points to a sharpened focus on advancing DMR-001 and preparing for future commercialization. Next, we examine how this leadership reshaping,...
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer
Damora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30. Jarrett, who will also join the Board of Directors, previously served as COO and CFO at Arcus Biosciences and held executive […]
Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price Momentum
CFO transition puts Damora Therapeutics (DMRA) in focus Damora Therapeutics (NasdaqCM:DMRA) is back on investors’ radar after the company announced that Lori Firmani has stepped down as Chief Financial Officer. Brian Burkavage has taken over the role. See our latest analysis for Damora Therapeutics. The CFO transition comes after a period of strong momentum, with a year to date share price return of 18.84% and a 1 year total shareholder return of around 7x, even though the 3 and 5 year total...
Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says
Damora Therapeutics (DMRA) is capitalizing on growing validation of using mutant calreticulin target
What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?
Does Galecto, Inc. (DMRA) have what it takes to be a top stock pick for momentum investors? Let's find out.